Income StatementBalance SheetCash FlowSegments
Becton, Dickinson and Company logo

Becton, Dickinson and Company Business Segments

Business, geographic, and product segment breakdowns

Becton, Dickinson and Company generates $22.2B in annual revenue across 4 key segments: BioPharma Systems (0.5), Connected Care (0.4), Interventional (0.8), and Medical Essentials (0.5). The company-wide operating margin is 10.78%. Based on the Q1 2026 filing.

BioPharma Systems53.6%Connected Care43.7%Interventional (TTM)80.8%Medical Essentials50.7%
Latest FilingQ1 2026
Report Date2026-05-07
Market Cap$39.8B
P/E Ratio34.98
ROE4.61%

Products & Services

Revenue, remaining performance obligation, amount

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Products and/or Services$2.3B$2.4B$2.5B$2.8B$2.5B$2.3B
Consumables$2.0B$2.2B$2.3B$2.3B$2.4B$2.0B

Loss contingency accrual, product liability, net

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Pyxis$50.0M$124.0M$114.0M$98.0M$83.0M$68.0M

Geographic

Long-Lived Assets

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
EMEA———$6.8B——
Greater Asia———$1.6B——
Other———$2.4B——

Business Segments

Goodwill, Foreign Currency Translation, Gain (Loss)

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Interventional$66.0M-$24.0M-$69.0M-$8.0M-$3.0M$13.0M
Medical Essentials————-$4.0M$6.0M
Connected Care————-$1.0M-$1.0M
BioPharma Systems————$0.0$0.0

Segment Cost of Products and Services Sold as a Percent of Revenues

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
BioPharma Systems55.4%53.2%——56.6%53.6%
Medical Essentials48.5%47.0%——50.1%50.7%
Connected Care45.0%44.8%——44.3%43.7%
Interventional32.1%31.7%——33.5%31.6%

Segment Operating Income (Loss) as a Percent of Revenues

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Interventional44.6%44.7%——42.1%42.7%
BioPharma Systems33.7%38.9%——32.6%38.1%
Medical Essentials38.3%39.3%——35.6%34.8%
Connected Care31.3%33.0%——31.1%31.0%

Segment Other Operating Expense (Income), net as a Percent of Revenues

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Connected Care0.6%0.2%——0.3%0.3%
BioPharma Systems0.0%0.0%——0.0%0.0%
Interventional0.0%0.0%——0.0%0.0%
Medical Essentials0.0%0.0%——0.0%0.0%
Medical0.1%0.1%0.1%0.1%——

Segment Research and Development as a Percent of Revenues

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Connected Care7.4%6.9%——7.5%8.1%
Interventional4.4%5.0%——4.7%5.3%
Medical Essentials2.8%3.1%——2.9%3.2%
BioPharma Systems4.1%3.1%——4.1%2.8%
Medical1.1%1.1%1.1%1.1%——

Segment Selling and Administrative as a Percent of Revenues

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Interventional18.9%18.6%——19.7%20.4%
Connected Care15.7%15.1%——16.9%17.0%
Medical Essentials10.4%10.4%——11.3%11.2%
BioPharma Systems6.8%4.8%——6.6%5.4%
Medical2.9%2.9%2.9%2.9%——

Cost of Products Sold as a Percent of Revenues

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Medical11.9%11.9%11.9%11.9%——

Segment, Expenditure, Addition to Long-Lived Assets

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Medical$117.3M$117.3M$117.3M$117.3M——

Segment Operating Income as a Percent of Revenues

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Medical9.0%9.0%9.0%9.0%——